anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Migraine is a headache disorder that affects public health and reduces the patient's quality of life. Preventive medication is necessary to prevent acute attacks and medication overuse headaches (MOH). Agomelatine is a melatonin antagonist.
AIMS: This study aimed to determine the effectiveness of agomelatine on the severity and frequency of migraine attacks.
METHODS: The study is a parallel randomized controlled trial with two groups of intervention and control. 400 patients were evaluated. Eligible individuals, including those with episodic migraine headaches without aura between the ages of 18 and 60 years who did not receive preventive treatment beforehand, were enrolled. Also, patients did not receive any specific medications for other diseases. Among these, 100 people met the inclusion criteria and entered the study. These subjects were randomly assigned to one of the two groups. The intervention group received 25 mg of agomelatine daily and the control group received B1. In this study, the effect of agomelatine on the frequency and severity of attacks, mean monthly migraine days (MMD), and migraine disability assessment (MIDAS), were assessed. The study was triple-blind and after three months, a post-test was performed. Data were analyzed using SPSS software.
RESULTS: A total of 100 patients were randomly assigned to either intervention or control groups. The prescriber physician and the data collector did not know about the allocation of patients to groups. Before the intervention, there was no significant difference in the headache frequency per month (t=-0.182, df = 98, p = 0.85), mean MMD (p = 0.17), headache severity (p = 0.076), and MIDAS (p = 0.091). After the study, there was a significant difference between the two groups in terms of the headache frequency per month (p = 0.009), and mean of MMD (p = 0.025). There was also a significant difference between pretest and posttest in two groups in the headache severity (p < 0.001) and MIDAS (p < 0.001).
CONCLUSION: Agomelatine can be used as a preventive medication for migraine without aura. It is suggested that agomelatine be studied in comparison with other preventive drugs for patients with migraine.
TRIAL RETROSPECTIVELY REGISTRATION: Trial Retrospectively registration= IRCT20230303057599N1. Date: 2023-5-24 The present study is a residency thesis approved by the Tehran University of Medical Sciences.
Chronic hepatitis C affects nearly three million Americans. Of these, 15% will develop liver cirrhosis and approximately 5% will progress to hepatocellular carcinoma. Treatment for chronic hepatitis C is limited to interferon-based therapy. Many patients decline or cannot tolerate interferon because of its serious side effects. Sho-saiko-to, an Asian herbal medicine consisting of seven botanicals, has demonstrated anti-fibrotic affect by inhibition of lipid peroxidation in hepatocytes and stellate cells in an animal study. It has also been demonstrated to prevent progression of cirrhosis to hepatocellular carcinoma in human trials. This study is a single arm, single center trial of Sho-saiko-to in patients with chronic active hepatitis from hepatitis C infection who cannot tolerate or who have specific contraindications to interferon therapy. Patients will receive 52 weeks therapy with Sho-saiko-to. Outcome will be assessed by comparing pre- and posttreatment liver biopsies. Patients will be said to respond if they have an improvement of two points or greater on a standard measure of liver histology. If five or more of 25 evaluable patients respond, Sho-saiko-to will be deemed worthy of further testing.
Participants receive ofatumumab IV over 4 hours once a week for 4 weeks, then monthly thereafter. Treatment continues for up to 12 months in the absence of disease progression or unacceptable toxicity.
Gingival phenotype (GP) should be determine in each dento-gingival unit as a 3D volume of gingiva with the following parameters: width of keratinized tissue (WKT) and gingival thickness (GT). The phenotype determination is extremely important during many dental procedures, such as in dental surgery, orthodontics, prosthetics or implantology because it allows to dental treatment planning and reduce the risk of complications. Previous methods of determining the gingival phenotype were based on the shape of the crowns of the upper incisors and transparency of the free gingiva. These methods are non-invasive, but innacurate. The gingival phenotype may be determined more precisely by using biometry of WKT and GT. There are several possible methods to measure the thickness of the gingiva, such as bone sounding, cone beam comuted tomography (CBCT) measurement or parallel profile radiographs, CBCT/CAD (CBCT and computer-aided design) and ultrasound method. The ultrasonic gingival tissue measurement (UGTM) method is non-invasive, removes the need for anesthesia, which may increases the volume of tissues, but requires the experience of the researcher. However, it is considered as effective and reproducible method of the measurement soft tissue thickness. CBCT/CAD/PDIP (CBCT/CAD and prosthetic-driven implant planning) method also can be used to establishing the gingival phenotype.

Measurements of WKT are most often carried out using a periodontal probe calibrated every 1mm. In each case, a necessary condition for the proper examination of the patient and determination of GP is healthy periodontium.
PURPOSE:To obtain a new compound useful as an external preparation for skin having protecting action on ultraviolet rays free from coloring reaction with a metal ion. CONSTITUTION:A compound of the formula (R<1> is H or methyl; R<2> is 8-18C alkyl or CH2-CH2-CO2R<3>; R<3> is 8-18C alkyl) such as 5-cinnamylidene-3-(2- ethylhexyl)hydantoin. The compound of the formula is obtained by condensing hydantoin with a cinnamaldehyde to give cinnamylidenehydantoin. Then cinnamylidenehydantoin is alkylated or subjected to addition reaction with an acrylic ester to give a compound of the formula. A base for an external preparation for skin is blended with 0.1-20wt.% of the compound of the formula to give an external preparation for skin. The external preparation for skin shows extremely excellent ultraviolet absorbing action on ultraviolet light (UV-A) at long wavelength of 320-400nm.
The safety and effectiveness of CREON for the treatment of exocrine pancreatic insufficiency have been established in pediatric patients.

Use of CREON for this indication is supported by two adequate and well-controlled trials in adult and pediatric patients 12 years and older (Study 1) and in pediatric patients 7 to 11 years of age (Study 2) along with supportive data from an open-label, single-arm, study in 18 pediatric patients 4 months to six years of age (Study 3). All three study populations consisted of patients with exocrine pancreatic insufficiency due to cystic fibrosis. The safety in pediatric patients 7 years of age and older in Studies 1 and 2 were similar to that observed adult patients [see Adverse Reactions (6.1) and Clinical Studies (14)]. 

In Study 3, patients received their usual pancreatic enzyme replacement therapy (mean dose of 7,000 lipase units/kg/day for a mean duration of 18.2 days) followed by CREON (mean dose of 7,500 lipase units/kg/day for a mean duration of 12.6 days). The mean daily fat intake was 48 grams during treatment with usual pancreatic enzyme replacement therapy and 47 grams during treatment with CREON. Adverse reactions that occurred in patients during treatment with CREON in Study 3 were vomiting, irritability, and decreased appetite [see Adverse Reactions (6.1)]. 

Dosages exceeding 6,000 lipase units/kg/meal have been reported postmarketing to be associated with fibrosing colonopathy and colonic strictures in pediatric patients less than 12 years of age. If there is a history of fibrosing colonopathy, monitor patients during treatment with CREON because some patients may be at risk of progressing to stricture formation. Do not exceed the recommended dosage of either 2,500 lipase units/kg/meal, 10,000 lipase units/kg/day, or 4,000 lipase units/g fat ingested/day in pediatric patients greater than 12 months of age without further investigation [see Dosage and Administration (2.2) and Warnings and Precautions (5.1)]. 

Crushing or chewing CREON capsules or mixing the capsule contents in foods having a pH greater than 4.5 can disrupt the protective enteric coating on the capsule contents and result in early release of enzymes, irritation of the oral mucosa, and/or loss of enzyme activity. Instruct the patient or caregiver of the following: consume sufficient liquids (juice, water, breast milk, or formula) to ensure complete swallowing, and visually inspect the mouth of pediatric patients less than 12 months of age to ensure no drug is retained in the mouth and irritation of the oral mucosa has not occurred [see Dosage and Administration (2.3) and Warnings and Precautions (5.2)].
<P>PROBLEM TO BE SOLVED: To provide a granule usable as a turbidity-forming agent, a method for producing the granule, and to obtain a bathing agent composition containing the granule.  <P>SOLUTION: The granule contains anatase-type titanium oxide and a water-soluble polymer. The bathing agent composition contains the granule. The method for producing the granule is also provided. By using the granule, the bathing agent composition having high preservation stability can be provided. The bathing agent composition can be packaged and preserved even in a paper container because of the high stability in the preservation. Good solubility and dispersibility can be obtained even in an area where the hardness of tap water is high.  <P>COPYRIGHT: (C)2004,JPO
Day 0 to Day 38 will be an observation period with no tamoxifen. On Days 35 and 38, participants will receive a single dose of vorinostat orally.
INTRODUCTION: The choice between a cementless taper wedge stem and a fit-and-fill stem in total Hip arthroplasty (THA) for various proximal femoral morphological types has not been thoroughly evaluated. This study aimed to compare the risk of stem-related complications between these two stem types in Dorr type A, B, and C femurs.
MATERIALS AND METHODS: From January 2015 through April 2021, we retrospectively reviewed 1995 cementless THA procedures. We stratified all procedures into three groups: Dorr type A (N = 360, 18.0%), B (N = 1489, 74.7%) and C (N = 146, 7.3%). The primary outcome domain was stem-related complications, including stem subsidence ≥ 3 mm, intraoperative fracture, periprosthetic fracture and aseptic stem loosening. We performed multivariate regression analysis to compare the risk of stem-related complication between the two stem types. Other factors included age, sex, body mass index, diagnosis, age-adjusted Charlson comorbidity index, stem alignment and canal fill ratio.
RESULTS: The incidence of stem-related complications in the taper wedge and fit-and-fill stem groups was 4.4% (N = 15) and 6.5% (N = 107), respectively. Fit-and-fill stems showed an increased risk of stem-related complications (aOR: 9.903, 95% CI: 1.567-62.597) only in Dorr type C femurs. No significant difference in risk was observed in Dorr type A and B femurs. Furthermore, the canal fill ratio at the lesser trochanter, 2 cm and 7 cm below the lesser trochanter, did not exhibit an association with stem-related complications in any Dorr type.
CONCLUSIONS: Concerning the risk of stem-related complications, the taper wedge stem was a better choice in Dorr type C femurs. However, there was no difference in risk between the taper wedge stem and fit-and-fill stem in Dorr type A and B femurs.
Patients were given placebo or pirfenidone capsules orally one week before radiotherapy, 200mg/ time, 3 times a day in the first week; 300mg/ time 3 times daily for the second week and 400mg/ time 3 times daily for the third to eighth week. Take it after a meal.
PURPOSE: To obtain thickened polysaccharides having high dispersibility in water by coating the particles of polysaccharides which do not contain anionic groups with hydrolyzed gelatin as thickening and viscosity-raising polysaccharides. CONSTITUTION: The polysaccharides which are natural or amidated pectin, such as xanthan and galactomannan, and do not substantially contain the anionic groups are used. The polysaccharides described above are coated with 0.5 to 5.0 wt.% hydrolyzed gelatin of a mol.wt. of 1000 to 50000 dalton. The polysaccharide particles are then granulated in the presence of a hydrolyzed gelatin soln., by which the thickening and viscosity-raising polysaccharides are obtd. The resulted thickener have the high dispersibility in the water and are used for production of instant products in food and medicaments or the like.
PURPOSE:An anti-infective agent containing a chitosan oligomer as an active constituent. CONSTITUTION:An anti-infective agent obtained by incorporating a chitosan oligomer prepared by decomposing natural chitin present in the shell of a crab, e.g. chitobiose, chitotriose, chitotetraose, chitopentaose or chitohexaose, as an active constituent therein. Since the chitosan oligmer is soluble in water, it is formulated into an injection, tablet, powder, etc., and adminsitered by intravenous injection, oral administration, etc. This agent exhibits improved anti-infective effect on various germs, e.g. fungi such as Candida albicans, Staphylococcus aureus and other Gram-positive and Gram-negative bacteria, and the effective dose thereof is 10-200mg/kg. EFFECT:The agent exhibits improved effect, e.g. rapid production of drug action, immunological hyperergasia action with almost no toxicity and side effect, etc.
Provided are a graphene bioelectronic device, a treatment and diagnosis nanoparticle, and an endoscope system. The graphene bioelectronic device comprises a graphene composite layer comprising two or more graphene layers. The graphene composite layer may comprise: a first graphene layer; a silver nanowire layer arranged on the first graphene layer; and a second graphene layer arranged on the silver nanowire layer. The treatment and diagnosis nanoparticle comprises: a metal nanorod; a porous shell enveloping the metal nanorod; and a thermosensitive polymer capsule layer enveloping the porous shell. The treatment and diagnosis nanoparticle allows a treatment to be effective since a composite treatment is possible, allows a targeted treatment to minimize side effects, allows additional diagnosis by imaging cancer cells and the like, and can improve the effectiveness of a treatment by active targeting. The endoscopic system comprises: an endoscope having a built-in camera; and a graphene bioelectronic device attached to the endoscope. The graphene bioelectronic device is placed above the camera, and the camera can film through the graphene bioelectronic device.
The present disclosure provides compositions for treating ischemic conditions in a subject, which may include hexosamine D-mannosamine (ManN). The method may comprise administering to the subject in need thereof an effective amount of ManN. The administration may be effective to promote endothelial cell proliferation and angiogenesis in the subject. The subject may be in need of induction of angiogenesis due to an ischemic condition caused by a disease or wound. The composition for inhibiting protein glycosylation in a cell may include ManN. Methods for inhibiting protein glycosylation in a cell can include administering an effective amount of ManN to the cell.
The present invention discloses a new application of sophocarpidine oxide for preparing a medicament used for treating ulcerative colitis. Sophocarpidine oxide has the advantages of low toxicity, and safe and convenient clinic use. After the sophocarpidine oxide is used for treating ulcerative colitis of a rat, the degree of the symptom expression and the pathological change of the rat are obviously lightened, and cytokine interleukin-1 beta(IL-1 beta), IL-2, IL-6 and IL-10 in blood serum are obviously reduced. The research of clinical tests indicates that the effective rate of the sophocarpidine oxide for treating patients who have ulcerative colitis is 47.83%. The therapeutic effect of the sophocarpidine oxide is similar to that of sulphasalazine, but the incidence rate (which is 8.7%) of adverse reaction is lower. Therefore, the sophocarpidine oxide is an effective and safe medicament for treating ulcerative colitis.
Part 2 single nighttime oral dose of JNJ-48816274 or placebo administered during each of 3 or 4 crossover periods separated by 7-9 days. The doses of JNJ-48816274 will be selected based on data from Part 1 (not to exceed 250 mg).
Hemostasis at the radial access site for subjects randomized to the SoftSeal®-STF hemostatic pad will be obtained by applying pressure at the point proximal and distal to the puncture site and removing the sheath. While still maintaining pressure, the SoftSeal®-STF hemostatic pad will be applied over the puncture site. The cath lab staff will allow a small amount of blood (\< 0.2 mL) to contact the surface of the hemostatic pad and then will apply constant pressure.
BACKGROUND: Evolution of the surgical approach for total hip arthroplasty (THA) has led to the development of the minimally invasive direct superior approach (DSA). It is hypothesized that the DSA reduces postoperative pain and hospital length of stay (LOS). We aimed to provide an overview of current evidence on clinical, functional, and radiological outcomes with respect to risk of revision, complications, pain scores, physical function, operative time, LOS, blood loss, radiological outcomes, and learning curve.
METHODS: A comprehensive search of Medline, Embase, Web of Science, Cochrane Central Register of Controlled Trials, and Google Scholar, reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses literature search extension guidelines, was conducted to identify studies evaluating clinical, functional, and radiological outcomes of the DSA. Quality assessment was performed using the Cochrane Risk of Bias tool and Newcastle-Ottawa Scale. The review protocol was prospectively registered in the International Prospective Registry of Systematic Reviews.
RESULTS: Seventeen studies were included, generally of moderate quality. Qualitative synthesis evidenced accurate implant positioning, short LOS, and a short learning curve. Conflicting findings were reported for postoperative complications compared with conventional approaches. Better functional outcomes were seen in the early postoperative period than the posterolateral approach (PLA). Outcomes such as blood loss and operative time exhibited conflicting results and considerable heterogeneity.
CONCLUSION: Based on moderate-certainty evidence, it is uncertain if the DSA provides short-term advantages over conventional approaches such as PLA. There is limited evidence on long-term outcomes post-THA using the DSA. Further studies and ongoing registry monitoring is crucial for continuous evaluation of its long-term outcomes.
LEVEL OF EVIDENCE: Level III. See Instructions for Authors for a complete description of levels of evidence.
BACKGROUND: The incidence of adjacent vertebral body re-fracture after percutaneous kyphoplasty (PKP) is associated with a number of variables, of which decreased bone mineral density is one of the major risk factors. Forearm bone mineral density (BMD) measurements are gaining attention because of their convenience and validity, but there is a lack of systematic research on the specific relationship between forearm BMD and the risk of adjacent vertebral re-fracture after PKP.
PURPOSE: To investigate the correlation between forearm BMD and the risk of adjacent vertebral re-fracture after PKP in osteoporotic vertebral compression fractures (OVCF) patients.
METHODS: Retrospective evaluation of 198 OVCF patients receiving PKP was conducted in this study. The patients were divided into two groups: the no-fracture group and the re-fracture group, according to whether or not they had undergone vertebral re-fracture. Obtain basic information about the patient's age, sex, body mass index, bone cement leakage, smoking history, diabetes history, and surgical segmentation. Using computed tomography, the mean Hounsfield unit (HU) values for the BMD of the L1 lumbar spine were determined. For the dual-energy X-ray BMD test, the distal one-third lengths of the patient's nondominant forearm's radius and ulna were chosen. Receiver operating characteristic curves were utilized to evaluate the predictive value of forearm BMD versus lumbar CT values for vertebral re-fracture, and univariate and multivariate logistic regression analyses were employed to identify characteristics related with vertebral re-fracture following PKP.
RESULTS: Re-fracture rate after PKP was 17.2% at a minimum 12-month follow-up. Significant differences were seen between the refracture and non-fracture groups in terms of hypertension, Cobb angle correction, vertebral height recovery rate, intradiscal cement leakage, forearm bone density, and vertebral HU values. In multifactorial logistic regression analysis, forearm bone density (OR 0.821; 95% CI 0.728-0.937, p = 0.008) and HU values (OR 0.815; 95% CI 0.733-0.906, p = 0.005) were independent risk factors for vertebral re-fracture. The area under the curve (AUC) for forearm BMD values and HU values predicting adjacent vertebral re-fracture were 0.956 and 0.967, respectively.
CONCLUSIONS: Forearm BMD is an independent risk factor for re-fracture of adjacent vertebrae after PKP. In addition, forearm BMD, as a valid indicator of postoperative re-fracture after PKP in patients with OVCF, and the HU value of lumbar spine CT were both powerful tools for predicting re-fracture.
BACKGROUND: Variants in SLC34A1 and SLC34A2 genes, which encode co-transporters NaPi2a and NaPi2c, respectively, can lead to hypophosphatemia due to renal phosphate loss. This condition results in hypercalcitriolemia and hypercalciuria, leading to formation of kidney stones and nephrocalcinosis. Phenotype is highly variable. Management includes hyperhydration, dietary modifications, and/or phosphate supplementation. Thiazides and azoles may be used, but randomized studies are needed to confirm their clinical efficacy.
METHODS: We conducted a retrospective study in the pediatric nephrology unit at Grenoble University Hospital from January 2010 to December 2023. The study aimed to describe clinical and biological symptoms of patients with confirmed SLC34A1 and SLC34A3 gene variants and their outcomes.
RESULTS: A total of 11 patients (9 females) from 6 different families had variants in the SLC34A1 (5 patients) and SLC34A3 (6 patients) genes. Median age at diagnosis was 72 [1-108] months. Average follow-up duration was 8.1 ± 4.5 years. Presenting symptom was nephrocalcinosis (4 cases), followed by renal colic (3 cases). At diagnosis, 90% of patients had hypercalciuria and 45% had hypercalcitriolemia. Management included hyperhydration and dietary advice. All patients showed favorable outcomes with normal growth and school attendance. One patient with an SLC34A3 variant showed regression of nephrocalcinosis. Kidney function remained normal.
CONCLUSION: Clinical and biological manifestations of SLC34 gene variants are highly variable, even among siblings; therefore, management must be personalized. Hygienic and dietary measures (such as hyperhydration, a low sodium diet, and age-appropriate calcium intake) result in favorable outcomes in most cases. Use of azoles (e.g., fluconazole) appears to be a promising therapeutic option.